D.C. Mun. Regs. tit. 29, § 925
[Repealed].
Effective Feb 12, 201057 DCR 1308, 1310Authority: The Director of the Department of Health Care Finance (DHCF), pursuant to the authority set forth in An Act to enable the District of Columbia to receive federal financial assistance under Title XIX of the Social Security Act for a medical assistance program, and for other purposes, approved December 27, 1967 (81 Stat. 774; D.C. Official Code § 1-307.02 (2006 Repl. & 2011 Supp.)) and section 6(6) of the Department of Health Care Finance Establishment Act of 2007, effective February 27, 2008 (D.C. Law 17-109; D.C. Official Code § 7-771.05(6) (2008 Repl.)). Source: Final Rulemaking published at 53 DCR 2401 (March 31, 2006); as amended by Final Rulemaking published at 57 DCR 1308, 1310 (February 12, 2010); as amended by Notice of Final Rulemaking published at 59 DCR 2298, 2299 (March 23, 2012).District of Columbia, Office of the Secretary
925 DEFINITIONS
925.1 For the purposes of this Chapter, the following terms and phrases shall have the meanings ascribed:
Brand - any registered trade name commonly used to identify a drug.
Container - a light resistant receptacle designed to hold a specific dosage form which is or maybe in direct contact with the item and does not interact physically or chemically with the item or adversely affect the strength, quality or purity of the item.
Department of Health Care Finance- the executive department responsible for administering the Medicaid program within the District of Columbia effective October 1, 2008.
DHCF – Department of Health Care Finance.
FUL – the federal upper limit established by CMS.
Multiple source drug – a drug marketed or sold by two (2) or more manufacturers or labelers.
PBM – pharmacy benefits manager
Prescribed drugs – Legend drugs approved as safe and effective by the U.S. Food and Drug Administration and those over-the-counter medications which fall into the following categories:
- (a) Oral analgesics with a single active ingredient (i.e., aspirin, acetaminophen, ibuprofen, etc.);
- (b) Ferrous salts (i.e., sulfate, gluconate, etc.);
- (c) Antacids with up to three active ingredients, (i.e., aluminum, magnesium, bismuth, etc.);
- (d) Diabetic preparations (i.e., insulin, syringes, etc.);
- (e) Pediatric, prenatal, and geriatric vitamin formulations;
- (f) Family planning drugs and supplies; and
- (g) Senna extract, single dose preparations when required for diagnostic radiological procedures performed under the supervision of a physician.
SOURCE: Final Rulemaking published at 53 DCR 2401 (March 31, 2006); as amended by Final Rulemaking published at 57 DCR 1308, 1310 (February 12, 2010).